Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928974 | 0.88 | FNTA (0.46) | FNTAFNTBCYP3A4CYP3A5GPR119 | |
| SCHEMBL30237690 | 0.87 | GPR119 (0.53) | PDE10AGPR119ALOX5APFEN1 | |
| SCHEMBL24574905 | 0.87 | GPR119 (0.53) | PDE10AGPR119ALOX5APFEN1 | |
| SCHEMBL23235671 | 0.87 | P2RX7 (0.45) | — | |
| SCHEMBL23929009 | 0.85 | GPR119 (0.51) | FNTAFNTBCYP3A4CYP3A5GPR119 | |
| SCHEMBL24320996 | 0.84 | GLP1R (0.53) | CYP3A4CYP3A5GPR119USP30MAPT | |
| SCHEMBL30583912 | 0.83 | DPP4 (0.45) | FNTAFNTBCYP3A4CYP3A5GPR119 | |
| SCHEMBL28786494 | 0.83 | DPP4 (0.46) | FNTAFNTBCYP3A4CYP3A5GPR119 | |
| SCHEMBL28543738 | 0.83 | P2RX7 (0.43) | — | |
| SCHEMBL24321002 | 0.82 | GPR119 (0.46) | CYP3A4CYP3A5GPR119POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3806855-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | FNTA 3648/4885FNTB 3558/4885PDE10A 284/4885 |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | FNTA 3648/4885FNTB 3558/4885PDE10A 284/4885 |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | FNTA 3648/4885FNTB 3558/4885PDE10A 284/4885 |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | FNTA 3648/4885FNTB 3558/4885PDE10A 284/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | FNTA 3648/4885FNTB 3558/4885PDE10A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.